stockrowNovartis AG
NVS Healthcare Drug Manufacturers General
Novartis AG’s revenue for fiscal 2025 (year ended December 2025) was $56.7 billion, up 9.57% from fiscal 2024.
- Revenue
- +4.67%
- EPS
- −69.1%
- Free cash flow
- −17.8%
- Total debt
- +53.9%
Quarter to September 2026, against a year earlier
Follow NVS
Alert me
Novartis AG (NVS) Revenue
Novartis AG's revenue for fiscal 2025 was $56.7B, up 9.57% from $51.7B in fiscal 2024. Over the twelve months to 30 September 2026 it was $57.4B. Over the past ten years it has ranged from $43.5B (fiscal 2022) to $56.7B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 3 consecutive fiscal years. Novartis AG ranks 8th of 18 Drug Manufacturers General companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $56.7B | 9.57% |
| FY2024 | $51.7B | 10.85% |
| FY2023 | $46.7B | 7.36% |
| FY2022 | $43.5B | (17.81%) |
| FY2021 | $52.9B | 5.97% |
| FY2020 | $49.9B | 2.51% |
| FY2019 | $48.7B | 5.59% |
| FY2018 | $46.1B | (8.05%) |
| FY2017 | $50.1B | 1.41% |
| FY2016 | $49.4B | (1.89%) |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $15.0B | 0.52% |
| Jun 2026 | $15.0B | 10.55% |
| Mar 2026 | $13.5B | (2.42%) |
| Dec 2025 | $13.9B | (3.47%) |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| JNJ Johnson & Johnson compare | $99.3B |
| MRK Merck & Co., Inc. compare | $67.4B |
| ABBV AbbVie Inc. compare | $66.0B |
| PFE Pfizer Inc. compare | $63.6B |
| AZN AstraZeneca PLC compare | $62.4B |
| NVS Novartis AG | $57.4B |
| NVO Novo Nordisk A/S compare | $51.5B |
| AMGN Amgen Inc. compare | $38.9B |
| GILD Gilead Sciences, Inc. compare | $31.0B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on NVS
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement